PSMA-GCK01: a generator-based 99mTc/188Re theranostic ligand for the prostate-specific membrane antigen
J Cardinale, FL Giesel, C Wensky… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) theranostics have been introduced with 68Ga
and 177Lu, the most used radionuclides. However, 188Re is a well-known generator-based …
and 177Lu, the most used radionuclides. However, 188Re is a well-known generator-based …
Preclinical evaluation of a novel radioligand therapy for patients with prostate cancer: biodistribution and efficacy of 177Lu-rhPSMA-10.1 in comparison with 177Lu …
C Foxton, R Grønlund, J Simon, B Cornelissen… - 2022 - Soc Nuclear Med
2567 Introduction: Theranostic radiohybrid prostate-specific membrane antigen (rhPSMA)
ligands offer the potential for 18 F-radiolabeling for use in diagnostic imaging or to be …
ligands offer the potential for 18 F-radiolabeling for use in diagnostic imaging or to be …
Preclinical development of a novel [68Ga]Ga-/[177Lu]Lu-labeled agent for PSMA-targeted imaging and therapy
Y Wu, X Zhang, H Zhou, J Zhang - Journal of Radioanalytical and Nuclear …, 2022 - Springer
Prostate-specific membrane antigen (PSMA)-targeted radiolabeled agents have been
developed to diagnose and treat prostate cancer. In this study, we developed a novel 68Ga …
developed to diagnose and treat prostate cancer. In this study, we developed a novel 68Ga …
[HTML][HTML] The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [99mTc] Tc-PSMA-GCK01 Compared to Dedicated …
E Mamlins, L Scharbert, J Cardinale, M Krotov… - Molecular imaging and …, 2024 - Springer
Purpose Radiolabeled PSMA-ligands play a major role in today's nuclear medicine. Since
approval of [177Lu] Lu-PSMA-617 for therapy of metastatic prostate cancer, availability of …
approval of [177Lu] Lu-PSMA-617 for therapy of metastatic prostate cancer, availability of …
Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer
M Schottelius, A Wurzer, K Wissmiller… - Journal of Nuclear …, 2019 - Soc Nuclear Med
The prostate-specific membrane antigen (PSMA)–targeted radiotracers 68Ga/177Lu-PSMA-
I&T and 99mTc-PSMA-I&S (for i maging and s urgery) are currently successfully used for …
I&T and 99mTc-PSMA-I&S (for i maging and s urgery) are currently successfully used for …
Therapeutic efficacy of a bivalent inhibitor of prostate-specific membrane antigen labeled with 67Cu
LE McInnes, C Cullinane, PD Roselt… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for
prostate cancer. We previously reported a ligand, 64Cu-CuSarbisPSMA, featuring 2 lysine …
prostate cancer. We previously reported a ligand, 64Cu-CuSarbisPSMA, featuring 2 lysine …
Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging
J Cardinale, M Schäfer, M Benešová… - Journal of Nuclear …, 2017 - Soc Nuclear Med
In recent years, several radiotracers targeting the prostate-specific membrane antigen
(PSMA) have been introduced. Some of them have had a high clinical impact on the …
(PSMA) have been introduced. Some of them have had a high clinical impact on the …
[HTML][HTML] Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
EAM Ruigrok, N van Vliet, SU Dalm, E de Blois… - European journal of …, 2021 - Springer
Purpose Various radiolabeled prostate-specific membrane antigen (PSMA)–targeting
tracers are clinically applied for prostate cancer (PCa) imaging and targeted radionuclide …
tracers are clinically applied for prostate cancer (PCa) imaging and targeted radionuclide …
Recent advances in prostate-specific membrane antigen-based radiopharmaceuticals
W Diao, H Cai, L Chen, X Jin, X Liao… - Current Topics in …, 2019 - ingentaconnect.com
Background: Prostate cancer (PCa) is the most common sex-related malignancy with high
mortality in men worldwide. Prostate-specific membrane antigen (PSMA) is overexpressed …
mortality in men worldwide. Prostate-specific membrane antigen (PSMA) is overexpressed …
Nonradioactive cell assay for the evaluation of modular prostate-specific membrane antigen targeting ligands via inductively coupled plasma mass spectrometry
M Holzapfel, M Mutas, S Chandralingam… - Journal of Medicinal …, 2019 - ACS Publications
The development of novel prostate-specific membrane antigen (PSMA)-targeted radioactive
theranostic agents is currently limited to facilities capable of working with high-energy …
theranostic agents is currently limited to facilities capable of working with high-energy …
Related searches
- psma gck01 membrane antigen
- psma gck01 hynic ipsma
- psma gck01 prostate cancer
- psma gck01 imaging characteristics
- psma gck01 tc edda
- cell assay membrane antigen
- bivalent inhibitor membrane antigen
- tc edda hynic ipsma
- therapeutic efficacy membrane antigen
- prostate cancer hynic ipsma
- preclinical evaluation 177lu psma
- prostate cancer preclinical evaluation
- imaging characteristics hynic ipsma
- prostate cancer imaging characteristics
- biodistribution and efficacy 177lu psma
- radioligand therapy 177lu psma